Effectiveness of highly active antiretroviral therapy among HIV-1 infected women

Journal of Epidemiology and Community Health

Volumn 56, Issue 2, 2002, Pages 153-159

  Gange, S J ^a   Barron Y ^a   Greenblatt, R M ^b   Anastos, K ^c   Minkoff, H ^d   Young, M ^e   Kovacs, A ^f   Cohen, M ^g   Meyer III, W A ^h   Munoz A ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g Jr Hospital of Cook County   (United States)

^h QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATOVAQUONE; AZITHROMYCIN; CD4 ANTIGEN; CD8 ANTIGEN; CLARITHROMYCIN; CLINDAMYCIN; CLOFAZIMINE; CLOTRIMAZOLE; COTRIMOXAZOLE; DAPSONE; ETHAMBUTOL; FANSIDAR; FLUCONAZOLE; ISONIAZID; KETOCONAZOLE; MICONAZOLE; NYSTATIN; PENTAMIDINE; PRIMAQUINE; PYRAZINAMIDE; PYRIMETHAMINE; RIFAMPICIN; UNINDEXED DRUG;

DISEASE CONTROL; HUMAN IMMUNODEFICIENCY VIRUS; WOMENS HEALTH;

ADOLESCENT; ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MYCOSIS; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MIDDLE AGED; UNITED STATES;

UNITED STATES;

EID: 0036151783     PISSN: 0143005X     EISSN: None     Source Type: Journal    
DOI: 10.1136/jech.56.2.153     Document Type: Article

References (56)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 lymphocyte counts of 200 per cubic millimeter or less
2. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
3. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients
4. Distinguishing efficacy, individual effectiveness and population effectiveness of therapies
5. Penetration and predictors of use of highly active antiretroviral therapy in a cohort of HIV-seropositive women
6. Protease inhibitor use among a community sample of people with HIV disease
7. Selection by indication of potent antiretroviral therapy usage in a large cohort of HIV-infected women
8. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS
9. Marginal structural models and causal inference in epidemiology
10. Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients
11. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: Comparison of cohort studies with randomized trials
12. Assessing the impact of highly active antiretroviral therapy on AIDS and death
13. Use of cohort studies for evaluating AIDS therapies
14. Use of observational data for evaluating AIDS therapies
15. The effectiveness of interventions on incubation of AIDS as measured by secular increases within a population
16. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study
17. Changing patterns of mortality across Europe in patients infected with HIV-1: EuroSIDA Study Group
18. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
19. Models of survival in HIV infection and their use in the quantification of treatment benefits
20. Decline in deaths from AIDS due to new antiretrovirals
21. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study: Swiss HIV Cohort Study
22. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration
23. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997
24. Increasing survival time after AIDS in Italy: The role of new combination antiretroviral therapies
25. Scope of the AIDS epidemic in the United States
26. Trends in HIV incidence among young adults in the United States
27. HIV/AIDS Surveillance Supplemental Report. Characteristics of persons living with AIDS at the end of 1997
28. Changes in survival among people with AIDS in Lazio, Italy from 1993 to 1998
29. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy
30. Sex differences in HIV-1 viral load and progression to AIDS
31. Association of race and gender with HIV-1 RNA levels and immunologic progression
32. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men
33. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
34. Viral dynamics in human immunodeficiency virus type 1 infection
35. Impact of the ovulatory cycle on virologic and immunologic markers in HIV-infected women
36. The care of HIV-infected adults in the United States
37. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study
38. Variations in the care of HIV-infected adults in the United States: Results From the HIV Cost Services Utilization Study
39. Socioeconomic status and survival of persons with AIDS before and after the introduction of highly active antiretroviral therapy
40. Barriers to getting needed services for Ryan White CARE clients
41. The Women's Interagency HIV Study (WIHS): Design, methods, sample, cohort characteristics and comparison with reported AIDS cases in US women
42. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
43. Retention of women enrolled in a prospective study of HIV infection: Impact of race, unstable housing, and use of HIV therapy
44. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
45. Random-effects models for longitudinal data
46. Positive effects of combined antiretroviral therapy on CD4+ T-cell homeostasis and function in advanced HIV disease
47. Accuracy of self-reports of AIDS and AIDS-related conditions in women
48. Factors associated with incident self-reported AIDS among women in the Women's Interagency HIV Study (WIHS)
49. Survivor treatment selection bias in observational studies: Examples from the AIDS literature
50. Methods to assess population effectiveness of therapies in HIV-1 incident and prevalent cohorts
51. Access to and utilization of primary care services among HIV-infected women
52. Barriers to care among persons living with HIV/AIDS in urban and rural areas
53. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States